Oocyte cryopreservation for fertility preservation in women with cancer and autoimmune disease.

Oocyte cryopreservation for fertility preservation in women with cancer and autoimmune disease. - Oocyte cryopreservation for fertility preservation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027163

Enrollment

Registered

2017-04-27

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, collagen disease

Interventions

We perform oocyte cryopreservation for patients before main treatment for primary disease.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with cancer or autoimmune disease. Patients whose physicians of primary disease make a written request for fertility preservation. Patients who are expected long term survival.

Exclusion criteria

Exclusion criteria: Patients who have malignancy in their ovary. Patients whose cancer may be sensitive to hormones.

Design outcomes

Primary

Measure	Time frame
The influence on progression of primary disease and treatment delay	—

Countries

Japan

Contacts

Public ContactHiroyuki Okimura

Kyoto Prefectural University of Medicine Department of obstetrics and gynecology

h-okim@koto.kpu-m.ac.jp075-251-5560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026